Fig. 7
Depletion of NK cells attenuates the antitumor activity of the αIL6 and RS504393 combination in orthotopic mouse models. A Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of either 1.0 × 106 MOC2 or MOC1 cells. Tumor-bearing mice were randomized to receive the combination treatment of the αIL6 (100 µg/mouse) and RS504393 (6 mg/kg), in the presence of αASGM1 or rabbit polyclonal IgG isotype (n = 10/group). B, C Individual and average MOC2 tumor growth curves. D, E Individual and average MOC1 tumor growth curves. F, G MOC2 and MOC1 tumor weight in each treatment group. *p < 0.05; **p < 0.01; ns: not significant